1.This study is a single-arm, open-label, single-infusion clinical study. In this trial, 11 subjects with KRAS G12V or G12D mutations and matching HLA-A*11:01 subtypes are recruited for autologous Tumor-T Cell Receptor (TCR) -Mediated T Cells therapy(TCR-T) therapy.Within 3 - 5 days after pretreatment, subjects will receive a single TCR-T infusion with an infusion dose of about 1 × 10⁹～1 × 10¹¹.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 will be injected intravenously for 14 days .The safety and tolerability of TCR-T therapy is assessed by observing adverse events after cell therapy.The effectiveness of the TCR-T treatment is assessed by comparing to the results or historical data from the subjects' own past standard treatment regimens.~2.6-8 weeks after the first TCR-T treatment, if the disease progress is evaluated, the second TCR-T treatment will be given, followed by DC vaccine injection . The day of second TCR-T treatment is marked as Day0. The administration scheme of TCR-T cells is the same as that described above. Day1 received the first intradermal DC vaccine . Before DC vaccine injection, patients will receive intradermal test dose (DC of 10³). After half an hour of observation of possible allergic reactions, the full dose will be injected intradermal in the lower abdominal area above the groin (1 × 10⁷dc 0.2ml) DC vaccine. After the first DC vaccine injection, the patient will receive another two doses of DC vaccine every two weeks, a total of three doses.
The primary aim of this study is to evaluate the safety and tolerability of TCR-T therapy .~The secondary aim is to assess the effectiveness and the pharmacokinetics / pharmacodynamics（PK/PD） characteristics of the TCR-T treatment and TCR-T cells combined with tumor antigen specific dendritic cells(DC cells)treatment.~The investigators will explore the changes of tumor microenvironment after treatment and evaluate the association of cytokines with neurotoxicity.